Announcements Trials
Browse Landscape

Phase

Phase NA 16Phase 3 2Phase 1 1

Status

Completed 10Unknown 5Withdrawn 2Terminated 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Polycystic Ovary Syndrome 1Neoplasms 1Motor Activity 1Insulin Resistance 1Body Weight 1Asthenia 1

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 48Radiotherapy 47Docetaxel 41Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Drug Therapy 14Irinotecan 13Imatinib Mesylate 13Filgrastim 13Zoledronic Acid 12Radiosurgery 12Erlotinib Hydrochloride 12Trastuzumab 11Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Exercise × Clear all
NCT01482286 2022-03-15

PULSE

Pennington Biomedical Research Center

Phase 3 Terminated
32 enrolled 10 charts

Body Weight, Insulin Resistance, Motor Activity, Polycystic Ovary Syndrome

NCT00273741 2009-12-07

Ritaline

University Hospital, Grenoble

Phase 3 Terminated
39 enrolled

Asthenia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡